stockrow
Saturday 7 November 2026
Export LNAI’s income statement to Excel — free account
Lunai Bioworks Inc.
LNAI Healthcare Biotechnology
Lunai Bioworks Inc.’s revenue for fiscal 2026 (year ended June 2026) was $52,000.00.
- EPS
- +99.0%
- Free cash flow
- −1.65%
Quarter to June 2026, against a year earlier
0.16
0.00
0.00%
Follow LNAI
Alert me
| Jun '26 | Jun '25 | Jun '24 | Jun '23 | Jun '22 | Jun '21 | Jun '20 | Jun '19 | Jun '18 | Jun '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — | — | — | — | — | — | — |
P/S ratio |
116.05 | — | — | — | — | — | — | — | — | — |
Altman Z-Score |
(76.96) | — | — | — | — | — | — | — | — | — |
P/FCF ratio |
0.00 | — | — | — | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(186.07) | — | — | — | — | — | — | — | — | — |
P/Operating CF |
(5.97) | — | — | — | — | — | — | — | — | — |
P/B ratio |
0.00 | — | — | — | — | — | — | — | — | — |
Price to Tangible BV |
0.00 | — | — | — | — | — | — | — | — | — |
EV/Sales |
110.63 | — | — | — | — | — | — | — | — | — |
EV/EBITDA |
0.00 | — | — | — | — | — | — | — | — | — |
EV/Operating CF |
(1.98) | — | — | — | — | — | — | — | — | — |
EV/FCF |
(1.97) | — | — | — | — | — | — | — | — | — |
Quick Ratio |
0.09 | 0.02 | 0.04 | 0.17 | 1.42 | 10.96 | 6.52 | 11.08 | 18.00 | 1.39 |
Current Ratio |
0.11 | 0.04 | 0.07 | 0.23 | 1.48 | 11.08 | 6.70 | 11.25 | 18.04 | 1.40 |
Net Debt/EBITDA |
0.20 | 0.03 | 0.01 | 0.10 | 0.21 | 0.65 | 0.25 | 1.12 | 2.94 | 1.65 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 5.41% | 3.05% | 3.25% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.48 | 0.04 | 0.12 | 0.30 | 0.14 | 0.77 | 0.92 | 0.47 | 0.69 | 0.55 |
Capex/Depreciation |
(0.01) | 0.00 | 0.00 | 0.00 | 0.00 | (0.12) | (1.01) | (10.00) | (1.62) | 0.00 |
Interest Coverage |
(40.47) | (310.14) | (33.53) | (66.44) | (311.37) | (61.65) | (114.32) | — | (37.19) | (91.27) |
| 23.46% | (321.81%) | (99.09%) | (66.63%) | (91.74%) | (15.68%) | (6.73%) | (10.86%) | (7.88%) | (478.68%) | |
| (39.21%) | (207.76%) | (79.87%) | (55.53%) | (82.73%) | (14.54%) | (6.38%) | (9.94%) | (6.75%) | (79.47%) | |
ROIC |
0.00% | 0.00% | (38.73%) | (54.00%) | (106.65%) | (9.15%) | (4.56%) | (4.27%) | (2.33%) | 0.00% |
Return on Tangible Assets |
21.13% | 641.66% | 317.73% | 499.25% | (3,065.27%) | (135.43%) | (136.16%) | (149.24%) | (42.32%) | (177.16%) |
Average Days of Receivables |
0.00 | — | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
47.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
15,000.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.79 | 0.74 | 0.98 | 0.93 | 0.87 | 0.88 | 0.94 | 0.93 | 0.91 | 0.03 |
Share Based Compensation of Revenue |
0.00% | — | — | — | — | — | — | — | — | — |
Graham Net Nets |
(1.54) | — | — | — | — | — | — | — | — | — |
Graham Number |
7.87 | — | — | — | — | — | — | — | — | — |
Earnings Yield |
(31.35%) | — | — | — | — | — | — | — | — | — |
Free Cash Flow Yield |
(48.34%) | — | — | — | — | — | — | — | — | — |
Revenue per Share |
0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.57) | (3.82) | (9.00) | (16.74) | (23.96) | (34.96) | (18.06) | (18.12) | (15.82) | (7.68) |
Capex per Share |
0.00 | 0.00 | (0.06) | (0.04) | (0.01) | (0.08) | (0.32) | (1.53) | (0.11) | 0.00 |
Free Cash Flow per Share |
(1.57) | (3.82) | (9.06) | (16.78) | (23.97) | (35.04) | (18.38) | (19.65) | (15.93) | (7.68) |
Cash per Share |
0.51 | 0.23 | 0.18 | 2.67 | 13.97 | 35.05 | 15.02 | 26.17 | 56.88 | 25.71 |
Shareholders Equity per Share |
(2.69) | (10.35) | 108.28 | 66.12 | 110.60 | 296.24 | 287.12 | 368.77 | 578.70 | 10.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(2.69) | (10.35) | 108.28 | 66.12 | 110.60 | 296.24 | 287.12 | 368.77 | 578.70 | 10.00 |
Free Cash Flow |
(5.29) | (7.87) | (11.04) | (11.80) | (15.74) | (20.66) | (10.64) | (9.22) | (4.37) | (1.18) |
Working Capital |
(16.87) | (28.11) | (28.31) | (8.46) | 3.11 | 19.01 | 7.61 | 11.38 | 14.89 | 1.21 |
Capital Expenditures |
0.00 | — | (0.07) | (0.03) | (0.01) | (0.05) | (0.18) | (0.72) | (0.03) | — |
Net Current Asset Value |
(16.93) | (28.53) | (29.15) | (9.23) | (2.45) | 5.96 | (2.89) | 5.72 | (8.00) | 1.21 |
EV/EBIT |
0.00 | — | — | — | — | — | — | — | — | — |
Capex to Sales |
0.02 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Price to Operating Income |
0.00 | — | — | — | — | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
14.46 | 463.79 | 113.99 | 38.16 | 159.72 | 0.58 | 0.23 | 0.10 | 0.68 | 0.00 |
Cash ROIC |
72.35% | 37.73% | (8.35%) | (24.40%) | (18.22%) | (10.27%) | (5.89%) | (4.98%) | (2.51%) | (21.51%) |
Accounts Receivable Turnover |
0.00 | — | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | 0.55 | — | — | 0.00 | 0.01 | 0.07 | 0.17 | 0.46 |
Average Payables |
12.47 | 11.00 | 7.37 | 3.35 | 0.86 | 0.46 | 0.68 | 0.79 | 0.74 | 0.93 |
Average Assets |
9.09 | 85.68 | 110.72 | 71.47 | 137.12 | 183.85 | 178.99 | 181.19 | 93.51 | 2.70 |
Average Common Equity |
(15.19) | 55.31 | 89.24 | 59.56 | 123.64 | 170.47 | 169.69 | 165.92 | 80.14 | 0.45 |
Columns are period end dates · fundamentals updated 2 Nov 2026